Related Experiment Videos
Advances in hepatitis A prevention in travellers
1Division of Epidemiology and Prevention of Communicable Diseases, University, Zurich, Switzerland.
Journal of Medical Virology
|December 1, 1994
Summary
A new double-strength hepatitis A vaccine offers long-lasting protection for travelers. A single dose provides immunity starting 14 days post-vaccination, with no significant adverse events reported.
Area of Science:
- Travel Medicine
- Vaccinology
- Infectious Diseases
Background:
- Hepatitis A is the most common vaccine-preventable infection among travelers.
- Hygienic precautions alone do not sufficiently mitigate hepatitis A risk for most travelers.
- Existing immunoglobulin prophylaxis offers shorter-term protection compared to newer vaccine options.
Purpose of the Study:
- To evaluate the efficacy and safety of a new double-strength hepatitis A vaccine for travelers.
- To compare the benefits of the new vaccine against traditional immunoglobulin prophylaxis.
- To address remaining questions regarding vaccination timing and applicability to young children.
Main Methods:
- Introduction of a double-strength hepatitis A vaccine (HAVRIX, 1440 ELISA units).
- Administration of a single vaccine injection.
- Monitoring for adverse events and duration of protection.
Main Results:
- A single dose provides protection from day 14 post-vaccination, lasting for 1 year.
- No significant adverse events were reported with the new vaccine.
- The vaccine offers superior and longer-lasting protection than immunoglobulin.
Conclusions:
- The double-strength hepatitis A vaccine is a significant advancement in travelers' health.
- Further research is needed to determine optimal protocols for travelers departing before 14 days and for immunizing very young children.